YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its business partner, EG Biomed US Inc. (“EG BioMed”) one of the Company’s licensing partners for pancreatic and breast cancer detection and with 3D Global to develop treatment for eye disorders, has been accredited by the College of American Pathologists’ (CAP) Laboratory Accreditation Program for its CLIA-certified laboratory in Bothell, Washington (CLIA Certificate #50D2316600).

Read more at globenewswire.com